Ignite Creation Date:
2024-07-17 @ 11:12 AM
Last Modification Date:
2024-10-26 @ 3:33 PM
Study NCT ID:
NCT06477263
Status:
RECRUITING
Last Update Posted:
2024-06-27
First Post:
2024-06-05
Brief Title:
NeuroCytotron in the Treatment of Autism Spectrum Disorder
Sponsor:
Neurocytonix Inc
Organization:
Neurocytonix Inc
Study Overview
Official Title:
Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder A Pilot Study
Status:
RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Preliminary Efficacy and Feasibility of Using NeuroCytotron in the Treatment of Autism Spectrum Disorder
Detailed Description:
Experimental pilot one-arm open-label single-center 13-month single-center study to evaluate the effect of NCX neuronal regeneration treatment in subjects with Autism Spectrum Disorder ASD to explore the therapeutic effects of NeuroCytonix neuronal regeneration technology on ASD symptoms Specific objectives include collecting preliminary safety and efficacy data assessing appropriate dosing and measuring the impact on participants quality of life after treatment
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None